Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial.
Hiroyuki TakashimaYoshinori YoshidaChinami NaguraTetsuya FurukawaRitsukou TeiTakashi MaruyamaNoriaki MaruyamaMasanori AbePublished in: Diabetes & vascular disease research (2018)
Canagliflozin was associated with slower progression of kidney disease and reduction in albuminuria and tubulointerstitial markers in diabetes patients with CKD.
Keyphrases
- type diabetes
- open label
- phase iii
- phase ii
- glycemic control
- study protocol
- clinical trial
- cardiovascular disease
- chronic kidney disease
- diabetic nephropathy
- phase ii study
- insulin resistance
- randomized controlled trial
- squamous cell carcinoma
- metabolic syndrome
- double blind
- weight loss
- placebo controlled
- adipose tissue